Advanced search
Publication Cover
Substance Use & Misuse Volume 53, 2018 - Issue 2: Medication-Assisted Treatment (MAT) for Opioid Addiction
Submit an article Journal homepage
3,280
Views
4
CrossRef citations to date
0
Altmetric
Original Articles

A Systematic, Intensive Statistical Investigation of Data from the Comprehensive Analysis of Reported Drugs (CARD) for Compliance and Illicit Opioid Abstinence in Substance Addiction Treatment with Buprenorphine/naloxone

Kenneth BlumDepartment of Psychiatry & McKnight Brain Institute, University of Florida College of Medicine, Gainesville, Florida, USA;Division of Addiction Services, Dominion Diagnostics, LLC, North Kingstown, Rhode Island, USA;Departments of Psychiatry & Behavioral Sciences, Keck School of Medicine of USC, Los Angeles, California, USA;Department of Psychology, Eötvös Loránd University, Institute of Psychology, Budapest, Hungary;Human Integrated Services Unit, University of Vermont Centre for Clinical & Translational Science, College of Medicine, Burlington, Vermont, USA;Division of Neuroscience Research & Addiction Therapy, Shores Treatment & Recovery Center, Port Saint Lucie, Florida, USA;Geneus Health, San Antonio, Texas, USACorrespondence[email protected] [email protected]
ORCID Iconhttp://orcid.org/0000-0001-6727-803X
ORCID Icon,
David HanDepartment of Management Science and Statistics, University of Texas at San Antonio, Texas, USA
,
Edward J. ModestinoDepartment of Psychology, Curry College, Milton, Massachusetts, USAORCID Iconhttp://orcid.org/0000-0001-7611-5144
ORCID Icon,
Scott SaundersDivision of Addiction Services, Dominion Diagnostics, LLC, North Kingstown, Rhode Island, USA
,
A. Kennison Roy IIIBehavioral Medical Corporation, Metairie, Louisiana, USA
,
W. JacobsDivision of Addiction Medicine, Medical College of Georgia, Augusta, Georgia, USA
,
Darryl S. InabaDivision of Alcohol & Drug Studies, University of Utah, Salt Lake City, Utah, USA
,
David BaronDepartments of Psychiatry & Behavioral Sciences, Keck School of Medicine of USC, Los Angeles, California, USA
,
Marlene Oscar-BermanDepartment of Psychiatry, Neurology, Anatomy & Neurobiology, Boston University School of Medicine, & VA Boston Healthcare System, Boston, Massachusetts, USA
,
Mary HauserDivision of Addiction Services, Dominion Diagnostics, LLC, North Kingstown, Rhode Island, USA
,
Rajendra D. BadgaiyanDepartment of Psychiatry, Icahn School of Medicine, New York, New York, USA
,
David E. SmithDepartment of Pharmacology, University of San Francisco, San Francisco, California, USA
,
John FeminoDivision of Addiction Services, Dominion Diagnostics, LLC, North Kingstown, Rhode Island, USA
&
Mark S. GoldDepartment of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA
 show all
Pages 220-229 | Published online: 19 Dec 2017

References

  • Balhara, Y. P., & Jain, R. (2012). A urinalysis-based study of buprenorphine and non-prescription opioid use among patients on buprenorphine maintenance. Journal of Pharmacology and Pharmacotherapeutics, 3(1), 15–19. doi:10.4103/0976-500x.92496
  • Baros, A. M., Latham, P. K., Moak, D. H., Voronin, K., & Anton, R. F. (2007). What role does measuring medication compliance play in evaluating the efficacy of naltrexone? Alcoholism, Clinical and Experimental Research, 31(4), 596–603. doi:10.1111/j.1530-0277.2007.00343.x
  • Bentzley, B. S., Barth, K. S., Back, S. E., & Book, S. W. (2015). Discontinuation of buprenorphine maintenance therapy: Perspectives and outcomes. Journal of Substance Abuse Treatment, 52, 48–57. doi:10.1016/j.jsat.2014.12.011
  • Blum, K., Chen, T. J., Bailey, J., Bowirrat, A., Femino, J., Chen, A. L., … Oscar-Berman, M. (2011). Can the chronic administration of the combination of buprenorphine and naloxone block dopaminergic activity causing anti-reward and relapse potential? Molecular Neurobiology, 44(3), 250–268. doi:10.1007/s12035-011-8206-0
  • Blum, K., Gold, M., Clark, H. W., Dushaj, K., & Badgaiyan, R. D. (2016). Should the United States government repeal restrictions on buprenorphine/naloxone treatment? Substance Use & Misuse, 51(12), 1674–1679. doi:10.1080/10826084.2016.1200097
  • Blum, K., Han, D., Femino, J., Smith, D. E., Saunders, S., Simpatico, T., … Gold, M. S. (2014). Systematic evaluation of “compliance” to prescribed treatment medications and “abstinence” from psychoactive drug abuse in chemical dependence programs: Data from the comprehensive analysis of reported drugs. PLoS One, 9(9), e104275. doi:10.1371/journal.pone.0104275
  • Chiang, C. N., & Hawks, R. L. (2003). Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug and Alcohol Dependence, 70(2 Suppl), S39–S47.
  • Elman, I., Borsook, D., & Volkow, N. D. (2013). Pain and suicidality: Insights from reward and addiction neuroscience. Progress in Neurobiology, 109, 1–27. doi:10.1016/j.pneurobio.2013.06.003
  • Fareed, A., Eilender, P., Ketchen, B., Buchanan-Cummings, A. M., Scheinberg, K., Crampton, K., … Drexler, K. (2014). Factors affecting noncompliance with buprenorphine maintenance treatment. Journal of Addiction Medicine, 8(5), 345–350. doi:10.1097/adm.0000000000000057
  • Gerra, G., Fantoma, A., & Zaimovic, A. (2006). Naltrexone and buprenorphine combination in the treatment of opioid dependence. Journal of Psychopharmacology, 20(6), 806–814. doi:10.1177/0269881106060835
  • Hill, E., Han, D., Dumouchel, P., Dehak, N., Quatieri, T., Moehs, C., … Blum, K. (2013). Long term Suboxone emotional reactivity as measured by automatic detection in speech. PLoS One, 8(7), e69043. doi:10.1371/journal.pone.0069043
  • Jaffe, J. H., & O'Keeffe, C. (2003). From morphine clinics to buprenorphine: Regulating opioid agonist treatment of addiction in the United States. Drug and Alcohol Dependence, 70(2 Suppl), S3–11.
  • Kumari, S., Manalai, P., Leong, S., Wooditch, A., Malik, M., & Lawson, W. B. (2016). Factors associated with non-adherence to buprenorphine-naloxone among opioid dependent African-Americans: A retrospective chart review. The American Journal on Addictions, 25(2), 110–117. doi:10.1111/ajad.12325
  • Lawford, B. R., Young, R. M., Noble, E. P., Sargent, J., Rowell, J., Shadforth, S., … Ritchie, T. (2000). The D(2) dopamine receptor A(1) allele and opioid dependence: Association with heroin use and response to methadone treatment. American Journal of Medical Genetics, 96(5), 592–598.
  • Lynch, F. L., McCarty, D., Mertens, J., Perrin, N. A., Green, C. A., Parthasarathy, S., … Pating, D. (2014). Costs of care for persons with opioid dependence in commercial integrated health systems. Addiction Science & Clinical Practice, 9, 16. doi:10.1186/1940-0640-9-16
  • Maas, J., Barton, G., Maskrey, V., Pinto, H., & Holland, R. (2013). Economic evaluation: A comparison of methadone versus buprenorphine for opiate substitution treatment. Drug and Alcohol Dependence, 133(2), 494–501. doi:10.1016/j.drugalcdep.2013.07.018
  • Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. The Cochrane Database of Systematic Reviews, 2, CD002207. doi:10.1002/14651858.CD002207.pub4
  • McCarberg, B. H. (2011). A critical assessment of opioid treatment adherence using urine drug testing in chronic pain management. Postgrad Med, 123(6), 124–31. doi:10.3810/pgm.2011.11.2502
  • McDermott, K. A., Griffin, M. L., Connery, H. S., Hilario, E. Y., Fiellin, D. A., Fitzmaurice, G. M., & Weiss, R. D. (2015). Initial response as a predictor of 12-week buprenorphine-naloxone treatment response in a prescription opioid-dependent population. Journal of Clinical Psychiatry, 76(2), 189–194. doi:10.4088/JCP.14m09096
  • Mokri, A., Chawarski, M. C., Taherinakhost, H., & Schottenfeld, R. S. (2016). Medical treatments for opioid use disorder in Iran: A randomized, double-blind placebo-controlled comparison of buprenorphine/naloxone and naltrexone maintenance treatment. Addiction, 111(5), 874–882. doi:10.1111/add.13259
  • Moore, B. A., Fiellin, D. A., Cutter, C. J., Buono, F. D., Barry, D. T., Fiellin, L. E., … Schottenfeld, R. S. (2016). Cognitive behavioral therapy improves treatment outcomes for prescription opioid users in primary care buprenorphine treatment. Journal of Substance Abuse Treatment, 71, 54–57. doi:10.1016/j.jsat.2016.08.016
  • NAABT, The National Alliance of Advocates for Buprenorphine Treatment. Suboxone Education: Opiates and Opioids heroin and morphine. Retrieved from https://www.naabt.org/education/opiates_opioids.cfm
  • Pal Singh Balhara, Y., & Jain, R. (2012). A urinalysis-based comparative study of treatment adherence on buprenorphine and buprenorphine/naloxone combination used as opioid substitution therapy. Innovations in Clinical Neuroscience, 9(7–8), 24–29.
  • Parran, T. V., Adelman, C. A., Merkin, B., Pagano, M. E., Defranco, R., Ionescu, R. A., & Mace, A. G. (2010). Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy. Drug and Alcohol Dependence, 106(1), 56–60. doi:10.1016/j.drugalcdep.2009.07.013
  • Policy, Office of National Drug Control. (2004). The Economic Costs of Drug Abuse in the United States, 1992–2002. ( Publication No. 207303). Washington, DC: Executive Office of the President
  • Rehm, J., Mathers, C., Popova, S., Thavorncharoensap, M., Teerawattananon, Y., & Patra, J. (2009). Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet, 373(9682), 2223–2233. doi:10.1016/s0140-6736(09)60746-7
  • Subramaniam, G. A., Warden, D., Minhajuddin, A., Fishman, M. J., Stitzer, ML., … Woody, G. E. (2011). Predictors of abstinence: National Institute of Drug Abuse multisite buprenorphine/naloxone treatment trial in opioid-dependent youth. J Am Acad Child Adolesc Psychiatry, 50(11), 1120–8. doi:10.1016/j.jaac.2011.07.010
  • Tam, W. M. (2017). Tests: Their Uses And Limitations. Drug Abuse2009/11 (pp. 31–36.). Retrieved from www.hkma.org/download/drugabuse2009/11.
  • Tkacz, J., Severt, J., Cacciola, J., & Ruetsch, C. (2012). Compliance with buprenorphine medication-assisted treatment and relapse to opioid use. The American Journal on Addictions, 21(1), 55–62. doi:10.1111/j.1521-0391.2011.00186.x
  • Volkow, N. D., Fowler, J. S., Wang, G., Telang, F., & Baler, R. (2009). Imaging dopamine's role in drug abuse and addiction. In L. Iversen, S. Dunnett, & A. Bjorklund (Eds.), Dopamine Handbook. London: Oxford University Press.
  • Volkow, N. D., Frieden, T. R., Hyde, P. S., & Cha, S. S. (2014). Medication-assisted therapies–tackling the opioid-overdose epidemic. The New England Journal of Medicine, 370(22), 2063–2066. doi:10.1056/NEJMp1402780
  • Warden, D., Subramaniam, G. A., Carmody, T., Woody, G. E., Minhajuddin, A., Poole, S. A., … Trivedi, M. H. (2012). Predictors of attrition with buprenorphine/naloxone treatment in opioid dependent youth. Addictive Behaviors, 37(9), 1046–1053. doi:10.1016/j.addbeh.2012.04.011
  • Wesson, D. R., & Smith, D. E. (2010). Buprenorphine in the treatment of opiate dependence. Journal of Psychoactive Drugs, 42(2), 161–175. doi:10.1080/02791072.2010.10400689

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.